{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:51:31Z","timestamp":1793159491435,"version":"4.5.0"},"reference-count":31,"publisher":"The Journal of Rheumatology","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2014,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objective.<\/jats:title>\n                    <jats:p>Rheumatoid factor (RF) and anticitrullinated protein antibodies (ACPA) are believed to be associated with more severe rheumatoid arthritis; however, studies in early inflammatory arthritis (EIA) have yielded conflicting results. Our study determined the prognosis of baseline ACPA-negative and RF-negative patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>Patients enrolled in the Canadian Early Arthritis Cohort had IgM RF and IgG anticyclic citrullinated peptide antibodies 2 (anti-CCP2) measured at baseline. Remission was defined as a Disease Activity Score of 28 joints (DAS28) &lt; 2.6 using logistic regression accounting for confounders at 12-month and 24-month followup.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>Of the 841 patients, 216 (26%) were negative for both RF and anti-CCP2. Compared to seropositive subjects, seronegative subjects were older (57 \u00b1 15 vs 51 \u00b1 14 yrs), more males proportionately (31% vs 23%), and had shorter length of symptoms (166 \u00b1 87 vs 192 \u00b1 98 days), and at baseline had higher mean swollen joint count (SJC; 8.8 \u00b1 6.8 vs 6.5 \u00b1 5.6), DAS28 (5.0 \u00b1 1.6 vs 4.8 \u00b1 1.5), and erosive disease (32% vs 24%, p &lt; 0.05). Treatment was similar between the 2 groups. At 24-month followup, seronegative compared to seropositive subjects had greater mean change (\u0394 \u00b1 SD) in disease activity measures: \u0394SJC counts (\u22126.9 \u00b1 7.0 vs \u22125.1 \u00b1 5.9), \u0394DAS28 (\u22122.4 \u00b1 2.0 vs \u22121.8 \u00b1 1.8), and \u0394C-reactive protein (\u221211.0 \u00b1 17.9 vs \u22126.4 \u00b1 17.5, p &lt; 0.05). Accounting for confounders, antibody status was not significantly associated with remission. However, at 12-month followup, ACPA-positive subjects were independently more likely to have new erosive disease (OR 2.94, 95% CI 1.45\u20135.94).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion.<\/jats:title>\n                    <jats:p>Although seronegative subjects with EIA have higher baseline DAS28 compared to seropositive subjects, they have a good response to treatment and are less likely to develop erosive disease during followup.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.140082","type":"journal-article","created":{"date-parts":[[2014,10,2]],"date-time":"2014-10-02T03:42:40Z","timestamp":1412221360000},"page":"2361-2369","source":"Crossref","is-referenced-by-count":97,"title":["Prognosis of Seronegative Patients in a Large Prospective Cohort of Patients with Early Inflammatory Arthritis"],"prefix":"10.3899","volume":"41","author":[{"given":"Lillian","family":"Barra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet E.","family":"Pope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Orav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Boire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boulos","family":"Haraoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Hitchon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward C.","family":"Keystone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Carter","family":"Thorne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Tin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian P.","family":"Bykerk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"and the CATCH Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2014,10,1]]},"reference":[{"key":"2018112909334332000_41.12.2361.1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20018"},{"key":"2018112909334332000_41.12.2361.2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-152-7-201004060-00010"},{"key":"2018112909334332000_41.12.2361.3","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq190"},{"key":"2018112909334332000_41.12.2361.4","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120736"},{"key":"2018112909334332000_41.12.2361.5","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20288"},{"key":"2018112909334332000_41.12.2361.6","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110234"},{"key":"2018112909334332000_41.12.2361.7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200421"},{"key":"2018112909334332000_41.12.2361.8","doi-asserted-by":"publisher","DOI":"10.1002\/art.38097"},{"key":"2018112909334332000_41.12.2361.9","doi-asserted-by":"publisher","DOI":"10.1002\/art.21385"},{"key":"2018112909334332000_41.12.2361.10","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.126821"},{"key":"2018112909334332000_41.12.2361.11","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.111284"},{"key":"2018112909334332000_41.12.2361.12","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1002\/art.24572","article-title":"Gene-environment interaction between the DRB1 shared epitope and smoking in the risk of anti-citrullinated protein antibody-positive rheumatoid arthritis: all alleles are important","volume":"6","author":"Lundstrom","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2018112909334332000_41.12.2361.13","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20207"},{"key":"2018112909334332000_41.12.2361.14","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.014233"},{"key":"2018112909334332000_41.12.2361.15","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.016808"},{"key":"2018112909334332000_41.12.2361.16","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.035691"},{"key":"2018112909334332000_41.12.2361.17","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-011-2260-9"},{"key":"2018112909334332000_41.12.2361.18","doi-asserted-by":"publisher","DOI":"10.1002\/art.24716"},{"key":"2018112909334332000_41.12.2361.19","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200379"},{"key":"2018112909334332000_41.12.2361.20","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-007-0343-4"},{"key":"2018112909334332000_41.12.2361.21","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-013-2236-0"},{"key":"2018112909334332000_41.12.2361.22","doi-asserted-by":"publisher","DOI":"10.1186\/ar2907"},{"key":"2018112909334332000_41.12.2361.23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200259"},{"key":"2018112909334332000_41.12.2361.24","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket011"},{"key":"2018112909334332000_41.12.2361.25","doi-asserted-by":"publisher","DOI":"10.1002\/art.37911"},{"key":"2018112909334332000_41.12.2361.26","doi-asserted-by":"publisher","DOI":"10.1002\/art.23763"},{"key":"2018112909334332000_41.12.2361.27","first-page":"815038","article-title":"A systematic review of serum biomarkers anti-cyclic citrullinated Peptide and rheumatoid factor as tests for rheumatoid arthritis","volume":"2011","author":"Taylor","year":"2011","journal-title":"Autoimmune Dis"},{"key":"2018112909334332000_41.12.2361.28","doi-asserted-by":"publisher","DOI":"10.1186\/ar2017"},{"key":"2018112909334332000_41.12.2361.29","doi-asserted-by":"publisher","DOI":"10.1186\/ar3505"},{"key":"2018112909334332000_41.12.2361.30","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1114465108"},{"key":"2018112909334332000_41.12.2361.31","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130742"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.140082","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T13:46:13Z","timestamp":1543499173000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.140082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,1]]},"references-count":31,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2014,12,1]]},"published-print":{"date-parts":[[2014,12]]}},"alternative-id":["10.3899\/jrheum.140082"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.140082","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,1]]}}}